Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term sacubitril/valsartan versus valsartan effects on cardiac efficiency in HFrEF
2017-002113-64Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sacubitril + valsartan and valsartan in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in cardiac efficiency after 6 weeks. Started Oct 2017; status: completed.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2017-002113-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002113-64.